Categories
Change Password!
Reset Password!
This study aimed to distinguish between the direct-acting antiviral (DAA) treatments and interferon (IFN) treatment concerning hepatocellular carcinoma (HCC) and survival.
Individuals
with chronic liver diseases cirrhosis triggered by
hepatitis B or hepatitis C infection, often
develops into hepatocellular carcinoma. Both the treatments i.e direct-acting antiviral
(DAA) and interferon (IFN) mentioned in this multi-institution
study of 338 patients, portrayed that the recurrence rates and patterns of hepatocellular
carcinoma did not differ among sustained virologic response patients via the PS
matching analysis.
This study aimed to distinguish between the direct-acting
antiviral (DAA) treatments and interferon (IFN) treatment concerning
hepatocellular carcinoma (HCC) and survival.
A total of 338 patients with chronic hepatitis C virus (HCV)
infection and prior HCC treatments who started IFN (88 patients, IFN group) or
DAA treatment (250 patients, DAA group) with sustained virologic response (SVR)
were examined. The propensity score (PS) matching was used to compare the
increasing HCC recurrence and survival rates between the 2 groups.
Sixty-three patients were chosen for each group following the matching. At 1 and 3 years, increased HCC recurrence rates were 20.6% and 34.6% in the IFN group and 19.2% and 43.0% in the DAA group, correspondingly. Between the two groups, no significant differences in HCC recurrence patterns were detected as depicted from the following graph 1:
Graph
1: Increasing HCC recurrence rates by antiviral
therapies following PS matching
At 1 and 3 years, the overall survival rates were 100% and 96.6% in the IFN group and 100% and 96.4% in the DAA group, correspondingly. The difference in overall survival rates between the 2 groups was not significant. Overall, there were no significant differences in HCC recurrence and overall survival rates were observed between the groups of patients receiving curative treatment (liver resection or radiofrequency ablation) for the most recent HCC prior to HCV therapy as seen in below graph 2:
Graph 1: Total survival rates by antiviral therapies
following PS matching
In patients
with IFN
and DAA therapy, the recurrence rates and patterns of
HCC and overall survival rates did not vary among patients with SVR.
Hepatology Research
Clinical outcomes of direct-acting antiviral treatments for hepatitis C patients after hepatocellular carcinoma are equivalent to interferon treatment
Yuki Tahata et al.
Comments (0)